Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program

by: Iola Bonggay

The Food and Drug Administration, otherwise referred to as FDA, is a federal government agency operating within the United States Department of Health and Human Services that is primarily responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs.

The grants and programs of the FDA are all geared towards the achievement of its primary agency mission which is to "protect consumers and enhance public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products."

In this capacity, the Food and Drug Administration has recently established the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program in an attempt to study the effects of various physicochemical properties of ophthalmic suspensions and emulsions on ocular bioavailability.

To this effect, the program will cover the key physicochemical properties which may impact clearance, distribution, and drug release; specifically globule/particle size distribution, surface change, osmolality, pH, viscosity, and dispersibility.

It is known that there are several kinds of opthalmic drugs which are available in the market today. The goal of this study is to determine which manufacturing differences may result in physicochemical differences which in turn may affect clearance, distribution, and release of the drug.

  (continued...)

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---

Health Resources and Services Administration: Affordable Care Act - Immediate Facility Improvements Program
The HRSA administers health care grants to eligible individuals, in order to help them obtain safe and quality care through the Affordable Care Act Capital Development (Immediate Facility Improvements Program).

---

Critical Congenital Heart Disease Newborn Screening Demonstration Program
The Health Resources and Services Administration has recently constituted the Critical Congenital Heart Disease (CCHD) Newborn Screening Demonstration Program in order to support and encourage the development, dissemination, and validation of screening protocols and newborn screening infrastructure for point of care screenings that are specific to Critical Congenital Heart Diseases.

---

Rheumatic Diseases Research Core Centers Project
The National Institutes of Health, in close cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has established a program entitled Rheumatic Diseases Research Core Centers Project wherein they intend to solicit applications for the development of Research Core Centers concentrating on rheumatic diseases.

---